Phase I/II ARROS-1 Study of Zidesamtinib (NVL-520) in ROS1 Fusion-positive Solid Tumours

Author(s):

The ARROS-1 Phase 1/2 study investigates the safety, tolerability, and efficacy of zidesamtinib (NVL-520), a ROS1-selective, brain-penetrant tyrosine kinase inhibitor, in heavily pre-treated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors, showing promising durable responses in both systemic and intracranial disease.

Disclaimers:

0:48 - Repotrectinib was approved in the US in 2023 with a line agnostic indication. Its market authorization application was validated by EMA in 2024, but it is not yet approved in Europe.
5:22 - 71% in the repotrectinib naive population, not 51%
8:15 - Speaker intended to reference G2032R mutation.